On November 23, 2020 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, reported that the Company will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference (Press release, BeiGene, NOV 23, 2020, View Source [SID1234571587]). Presentations will be available for registered attendees via the Piper Sandler conference site from November 23 to December 3, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An archived replay will be available for 90 days following the event in the investors section of BeiGene’s website at View Source or View Source

On November 23, 2020 NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, reported that management will participate in one-on-one investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2-3, 2020 (Press release, NuVasive, NOV 23, 2020, View Source [SID1234571608]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A pre-recorded fireside chat with management will be available to registered attendees of the conference during the week of November 23, 2020 and available online from the Investor Relations page of the Company’s website at www.nuvasive.com. A replay of the presentation will remain available on the website for 30 days.

On November 23, 2020 Myovant Sciences (NYSE: MYOV), a healthcare company reported on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences (Press release, Myovant Sciences, NOV 23, 2020, https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-present-upcoming-december-investor-conferences [SID1234571588]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 1, 2020 at 4:45 p.m. Eastern time. Lynn Seely, M.D., chief executive officer of Myovant Sciences, Inc., and Frank Karbe, president and chief financial officer of Myovant Sciences, Inc., will participate in a webcast presentation. Management will also participate in virtual one-on-one investor meetings on December 1.

Piper Sandler 32nd Annual Virtual Healthcare Conference. A pre-recorded presentation by Dr. Seely will be available at 10 a.m. Eastern time today on the investor relations page of Myovant’s website, investors.myovant.com. Management will participate in virtual one-on-one investor meetings on December 3, 2020.
The presentations will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.

On November 23, 2020 Boston Scientific Corporation (NYSE: BSX) reported to participate in the 2020 Evercore ISI HealthCONx Conference on December 1 (Press release, Boston Scientific, NOV 23, 2020, View Source [SID1234571611]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mike Mahoney, chairman and chief executive officer, and Susie Lisa, vice president, Investor Relations will participate in a 45-minute question-and-answer session with the host analyst beginning at approximately 8:00 a.m. EST.

A live webcast and replay of the webcast will be accessible at investors.bostonscientific.comView Source The replay will be available beginning approximately one hour following the completion of each event.

On November 23, 2022 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, reported that it participated in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held on December 1-3, 2020 (Press release, Cue Biopharma, NOV 23, 2020, View Source [SID1234608287]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The pre-recorded presentation will be available to participants during the conference and on the Events page of the Investors & Media section of the Company’s website www.cuebiopharma.com beginning today, November 23, 2020 at 10:00 a.m. EST. An archived version of the recording will be accessible for 90 days following the event.